SPECTROPHOTOMETRIC DETERMINATION OF PIPERIDINE 7-PROPYL-3-METHYLXANTHINE-8-YLTHIOACETATE
DOI:
https://doi.org/10.11603/2312-0967.2022.4.13735Keywords:
piperidine 7-propyl-3-methylxanthine-8-ylthioacetate, quantitative determination, UV spectrophotometry, validationAbstract
The aim of the work. Development and validation of UV spectrophotometric method for the quantitative determination of piperidine 7-propyl-3-methylxanthine-8-ylthioacetate.
Materials and Methods. The object of the study is a substance of piperidine 7-propyl-3-methylxanthine-8-ylthioacetate. The solvent – purified water. Analytical equipment: Specord 200 spectrophotometer (Analytic Jena AG, Germany), electronic laboratory scales (RADWAG XA 210.4Y), the ultrasonic bath (Sonorex Digitec DT100H), measuring utensils (Class A).
Results and Discussion. The band observed at 260–340 nm with a maximum of light absorption at 295 nm was selected to develop the method for the quantitative determination of this substance. According to the requirements of the SPU, the forecast of complete uncertainty of the methodology was calculated, as well as the validation of the methodology according to such validation characteristics as range of application, linearity, precision, accuracy and robustness. The range of application of the technique is in the range of 60–140 %. The calculated numerical values of linear dependence indicate that the method is linear in the whole range of application methods. The calculated confidence interval does not exceed the maximum allowable uncertainty of the analysis, which indicates that the method is accurate at the level of convergence. It is proved that the systematic error δ, which is introduced by the instability of the analyzed solution, does not exceed the critical value of maxδ, ie the solution remains stable for at least 1 hour.
Conclusion. The UV spectrophotometric method for the quantitative determination of piperidine 7-propyl-3-methylxanthine-8-ylthioacetate has been developed and validated.
References
Kovalenko VM. COMPENDIUM 2019 – medicinal products. [КОМПЕНДІУМ 2019 – лікарські засоби] Kyiv: Morion 2019. 2480 p. Ukrainian.
Vardanyan RS. Synthesis of Essential Drugs. Netherlands: Elsevier 2006. 617 р.
Radhakrishnam RR, Gangarapu K, Adharvana CM, Ravichandar M, Devarakonda KP, Boyina HK, VasudhaB, et al. Design, synthesis and biological evaluation of theophylline containing variant acetylene derivatives as α-amylase inhibitors. Bioorganic Chemistry. 2019; Vol. 92: 103120. https://doi.org/10.1016/j.bioorg.2019.103120.
Qing L, Liuwei M, Siru Z, Xiaoyan D, Na W, Yi J, Yichun P, et al. Rapid generation of novel benzoic acid-based xanthine derivatives as highly potent, selective and long acting DPP-4 inhibitors: Scaffold-hopping and prodrug study. European Journal of Medicinal Chemistry. 2019; Vol. 180: 509–523. https://doi.org/10.1016/j.ejmech.2019.07.045.
Lupascu FG, Dash M, Samal SK, Dubruel P, Lupusoru CE, Lupusoru RV, Dragostin O. Development, optimization and biological evaluation of chitosan scaffold formulations of new xanthine derivatives for treatment of type-2 diabetes mellitus. European Journal of Pharmaceutical Sciences. 2015;77: 122-34. https://doi.org/10.1016/j.ejps.2015.06.008.
Georgieva M, Kondeva-Burdina M, Mitkov J, Tzankova V, Momekov G, Zlatkov A. Determination of the antiproliferative activity of new theobromine derivatives and evaluation of their in vitro hepatotoxic effects. Anti-Cancer Agents in Medicinal Chemistry. 2016;16(7): 925-32.
Borowiecki P, Wińska P, Bretner M, Gizińska M, Koronkiewicz M, Staniszewska M. Synthesis of novel proxyphylline derivatives with dual Anti-Candida albicans and anticancer activity. European Journal of Medicinal Chemistry. 2018;150: 307-333. https://doi.org/10.1016/j.ejmech.2018.02.077.
Nivedita S, Swagata P, Sanjukta P. Identification of Xanthine Derivatives as Inhibitors of Phosphodiesterase 9A Through In silico and Biological Studies. Combinatorial Chemistry and High Throughput Screening. 2018;21(7): 476-86. https://doi.org/10.2174/1386207321666180821100713.
The State Pharmacopoeia of Ukraine. [Державна фармакопея України] Kharkiv: Ukrainian Scientific Pharmacopoeia Center of Quality of Medicinal Products. 1 ed. Х; 2001; 556 p. Ed. 1. 2004; 520 p. Ed. 2. Kharkiv: Ukrainian Scientific Pharmacopoeia Centerof Quality of Medicinal Products. 2008; 620 p. Ed 3. 2009; 280 p. Ed. 4. 2011; 540 p. Ukrainian.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Pharmaceutical Review / Farmacevtičnij časopis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
